Karyopharm Therapeutics (NASDAQ:KPTI) Receives “Outperform” Rating from Royal Bank of Canada
Royal Bank of Canada reiterated their outperform rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI – Free Report) in a report released on Wednesday, Benzinga reports. They currently have a $3.00 price objective on the stock. A number of other research firms have also commented on KPTI. Robert W. Baird reduced their target price on Karyopharm […]
More Stories
Trump Calls Iran’s Response to Peace Proposal ‘Totally Unacceptable’
By Tom Gantert U.S. President Donald Trump on May 10 rejected Iran’s response to the latest peace proposal pitched by...
Iran Turns to China Rail Link to Bypass US Blockade, but It Has Limited Effect, Analysts Say
By Alex Wu As the U.S. military continues to blockade Iranian ports, Iran has increased overland railway shipment with China...
Passengers Evacuate Cruise Ship Hit by Deadly Hantavirus Outbreak
By Tom Gantert The passengers and crew aboard the MV Hondius exited the hantavirus-stricken cruise ship in the Canary Islands...
Hantavirus Symptoms Reported on Cruise Evacuation Flight
By Tom Gantert A French citizen on the MV Hondius cruise ship came down with hantavirus symptoms while flying back...
Less Than 11 Percent of New Construction Is in Urban Areas, Report Finds
By Mary Prenon Newly built homes across America are scarce in urban areas and carry a significant price premium, according...
US Forces Prevent 70 Tankers From Entering or Leaving Iranian Ports
By Naveen Athrappully The U.S. military is currently blocking more than 70 tankers from entering or leaving Iranian ports amid...